drugset / Trial / NCT00625274

A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients

NCT00625274

Phase 4 Completed 100 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

This study looks at controlling intragastric pH following administration of esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg taken orally, once daily in patients taking either non-selective or cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drugs (NSAIDs).

Timeline

Start
2004-06
Primary completion
2004-11
Completion
2004-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg Oral
Subject Lansoprazole Other / unclassified 30 mg Oral
Subject Pantoprazole Other / unclassified 40 mg Oral